Alain Katic
Child & Adolescent Psychiatry · Bellaire, TXNPI 1871605741
Payments from drug & device makers
Across 1,233 payments — averaging $1303.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$405K
- AbbVie$390K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$301K
- Corium, LLC$193K
- Boehringer Ingelheim International GmbH$107K
- Janssen Research & Development, LLC$95K
- plus $115K from 27 others
Across 36 payments — averaging $2904.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Arbor Pharmaceuticals, Inc.$96K
- Pfizer$6K
- Supernus Pharmaceuticals, Inc.$2K
- AbbVie$919
What the payments were for
- Consulting fees$1,5001%
- Speaking & faculty fees$80,76076%
- Travel & lodging$5,9326%
- Food & beverage$17,60517%
- Education$220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$72,117
- Jornay PM 20mg capsules (Bottle of 100)$4,251
- Dyanavel XR$3,728
- Quillivant$3,604
- Quillichew ER$3,604
- Azstarys$1,700
- Adzenys XR-ODT$117
- Cotempla XR-ODT$117
- SPRAVATO$111
How this compares
$1,606,806 in reported general payments places this provider in the 95th percentile of 301 child & adolescent psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrintellixVortioxetine Hydrobromide | 20 | $9,376 |
| Lisdexamfetamine Dimesylate | 31 | $6,795 |
| CymbaltaDuloxetine Hcl | 12 | $6,775 |
| VyvanseLisdexamfetamine Dimesylate | 16 | $5,972 |
| MydayisDextroamphetamine/Amphetamine | 12 | $4,095 |
| Dextroamphetamine Sulfate | 28 | $3,132 |
| Bupropion XlBupropion Hcl | 104 | $2,013 |
| Methylphenidate ErMethylphenidate Hcl | 15 | $1,997 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 74 | $1,916 |
| Clozapine | 13 | $1,504 |
| Zolpidem Tartrate | 48 | $1,372 |
| Clonazepam | 63 | $1,045 |
| Alprazolam | 97 | $977 |
| Aripiprazole | 30 | $917 |
| Duloxetine Hcl | 37 | $819 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $929 | $15,34836 claims |
| Shire North American Group IncMydayis | $3,873 | $4,09512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 301 child & adolescent psychiatry providers in Texas.
Other child & adolescent psychiatry in Bellaire
- Steven PliszkaSan Antonio$194K
- Humera ChowdharyDenton$120K
- Farida AliFort Worth$75K
- Graham EmslieDallas$73K
- Rosa GonzalezBeaumont$55K
- Mary Garcia HolguinSan Antonio$24K
- Jeremy LankfordHouston$20K
- Cristian ZeniHouston$15K
- John SteffekSpring$14K
- Robert MosquedaEdinburg$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.